P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patientsECCO '18 Vienna
2018
P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s diseaseECCO '18 Vienna
2018
P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort seriesECCO '18 Vienna
2018
P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatmentsECCO '18 Vienna
2018
P581: Patient-reported complementary and alternative medicine use in IBD: 10 years of observation among patients included in a national cohortECCO '18 Vienna
2018
P584: Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnetECCO '18 Vienna
2018
P585: Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015ECCO '18 Vienna
2018
P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitisECCO '18 Vienna
2018
P587: Drug survival of vedolizumab-treated inflammatory bowel disease patients in a nationwide observational cohort study: ICC case seriesECCO '18 Vienna
2018
P588: Switching from infliximab originator to a first biosimilar is safe and effective: A single-centre series with through levels and anti-drug antibodies determinationECCO '18 Vienna
2018
P589: Adherence to medical treatment in patients with inflammatory bowel diseaseECCO '18 Vienna
2018
P592: Efficacy of vedolizumab for induction and maintenance of clinical remission in ulcerative colitis: The UCLH experienceECCO '18 Vienna
2018
P593: Efficacy, tolerance and safety of low-volume bowel preparations in inflammatory bowel diseases: Results from a French national multicentre studyECCO '18 Vienna
2018